Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2020 | Immunotherapy for TNBC: IMpassion130 & KEYNOTE-355

Sara Tolaney • 19 May 2020
ESMO Breast 2020
Breast Cancer Antibodies Atezolizumab Checkpoint Inhibitors Gemcitabine Nab-paclitaxel
IMpassion130

Sara Tolaney, MD, MPH, Dana Farber Cancer Institute, Boston, MA, outlines the role of immunotherapy in triple-negative breast cancer (TNBC), discussing IMpassion130 (NCT02425891) and KEYNOTE-355 (NCT02819518) trials. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Sara Tolaney

Optimizing ADCs in mBC: boosting efficacy & managing toxicity in earlier treatment lines
1:11
Optimizing ADCs in mBC: boosting efficacy & managing toxicity in earlier treatment lines
Sara Tolaney • 20 Oct 2025
ADCs in earlier-line metastatic breast cancer: insights from DESTINY-Breast09 & ASCENT-03
2:02
ADCs in earlier-line metastatic breast cancer: insights from DESTINY-Breast09 & ASCENT-03
Sara Tolaney • 20 Oct 2025
Remaining questions surrounding the use of T-DXd in the curative-intent setting
2:02
Remaining questions surrounding the use of T-DXd in the curative-intent setting
Sara Tolaney • 20 Oct 2025
T-DXd vs T-DM1 in high-risk HER2+ breast cancer: DESTINY-Breast05 interim data
1:51
T-DXd vs T-DM1 in high-risk HER2+ breast cancer: DESTINY-Breast05 interim data
Sara Tolaney • 20 Oct 2025

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals